Jasper Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Jasper Therapeutics (JSPR).

Price Target Range — 11 Quarters

Analyst Consensus — 13 Analysts

1S.Buy

7Buy

5Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$8Upside to Avg. PT+1541.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	William Blair	Matt Phipps	Reinstates	Outperform	—
Aug 12, 2026	Piper Sandler	Biren Amin	Initiate	Overweight	$2
May 15, 2026	TD Cowen	Yaron Werber	Downgrade	Buy→Hold	—
May 15, 2026	RBC Capital	Leonid Timashev	PT Cut	Sector Perform	$4→$3
Apr 1, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$12→$7
Mar 23, 2026	UBS	David Dai	Assumes	Neutral	$2
Nov 11, 2025	RBC Capital	Leonid Timashev	PT Cut	Sector Perform	$5→$4
Sep 22, 2025	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$20→$14
Sep 22, 2025	JMP Securities	Silvan Tuerkcan	PT Cut	Market Outperform	$12→$6
Sep 22, 2025	BTIG	Justin Zelin	PT Cut	Buy	$20→$7
Aug 15, 2025	UBS	Trung Huynh	PT Cut	Buy	$29→$25
Jul 8, 2025	BMO Capital	Kostas Biliouris	Downgrade	Outperform→Market Perform	$15→$4
Jul 8, 2025	JMP Securities	Silvan Tuerkcan	PT Cut	Market Outperform	$70→$12
Jul 8, 2025	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$50→$20
Jul 7, 2025	William Blair	Matt Phipps	Downgrade	Outperform→Market Perform	—
Jul 7, 2025	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$40→$20
Jul 7, 2025	Cantor Fitzgerald	Pete Stavropoulos	Downgrade	Overweight→Neutral	—
Jul 7, 2025	BTIG	Justin Zelin	PT Cut	Buy	$64→$20
May 15, 2025	Oppenheimer	Jay Olson	PT Cut	Outperform	$80→$65
May 13, 2025	UBS	Trung Huynh	PT Cut	Buy	$38→$33

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
William Blair Reinstates Outperform on Jasper Therapeutics

William Blair analyst Matt Phipps reinstates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform.

Benzinga Newsdesk

PRO
Piper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2

Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Overweight rating and announces Price Target of $2.

Benzinga Newsdesk

Jasper Closes Kira Deal, Extends Cash Runway

Jasper Therapeutics (JSPR) acquires Kira Pharma & raises $132M, extending its cash runway into 2028. Shares surge 20%+.

Vandana Singh

PRO
TD Cowen Downgrades Jasper Therapeutics to Hold

TD Cowen analyst Yaron Werber downgrades Jasper Therapeutics (NASDAQ:JSPR) from Buy to Hold.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3

RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Perform and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7

Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target from $12 to $7.

Benzinga Newsdesk

Jasper Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Jasper Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
William Blair Reinstates Outperform on Jasper Therapeutics

PRO
Piper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2

Jasper Closes Kira Deal, Extends Cash Runway

PRO
TD Cowen Downgrades Jasper Therapeutics to Hold

PRO
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3

PRO
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7

People Also Watch

People Also Watch

Jasper Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Jasper Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWilliam Blair Reinstates Outperform on Jasper Therapeutics

PROPiper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2

Jasper Closes Kira Deal, Extends Cash Runway

PROTD Cowen Downgrades Jasper Therapeutics to Hold

PRORBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3

PROEvercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7

People Also Watch

People Also Watch

PRO
William Blair Reinstates Outperform on Jasper Therapeutics

PRO
Piper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2

PRO
TD Cowen Downgrades Jasper Therapeutics to Hold

PRO
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3

PRO
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7